The Effect of Simvastatin on Nitric Oxide and hs-CRP Levels in patients with Liver Cirrhosis at Dr. Moewardi Hospital, Surakarta by Hariyanto, Budhi et al.
Hariyanto et al./ The Effect of Simvastatin on Nitric Oxide 
e-ISSN: 2549-0265   9 
The Effect of Simvastatin on Nitric Oxide and 
hs-CRP Levels in patients with Liver Cirrhosis 
at Dr. Moewardi Hospital, Surakarta 
 
Budhi Hariyanto1), Paulus Kusnanto2), Bambang Purwanto2) 
 
1)Masters Program in Family Medicine, Universitas Sebelas Maret 
2)Departement of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret/ 
Dr. Moewardi Hospital, Surakarta 
 
ABSTRACT 
 
Background: The prevalence of liver cirrhosis (SH) worldwide is at the seventh place as the 
cause of death. Increased pressure in the portal vein Portal Hypertension (HP) causes esopha-
geal varices and the more likely the patient to bleed. Endothelial dysfunction in cirrhosis of the 
liver causes a decrease in nitric oxide (NO) levels resulting in an imbalance between relaxation 
factors and portal vein contractions and increasing hs-CRP levels. Simvastatin can increase NO 
levels and improve endothelial dysfunction in patients with SH and can reduce levels of hs-CRP. 
This study aimed determine the effect of simvastatin administration on nitric oxide and hs-CRP 
level in patients with liver cirrhosis. 
Subjects and Method: This was a randomized controlled trial conducted at Dr. Moewardi 
hospital, Surakarta, Central Java. A sample of 29 patients was divided into treatment and 
control groups. 14 patients in treatment group were given simvastatin dose 20 mg. 15 patients in 
control group received placebo. The dependent variable was nitric oxide and hs-CRP levels. The 
independent variable was Simvastatin administration. Nitric oxide serum level was measured by 
an enzyme linked immunosorbent assay (ELISA). Hs-CRP level was measured by immune-
chemiluminescent method. The data were analyzed by t test. 
Results: NO level after Simvastatin 20 mg administration (Mean= 7.93 µg/mL; SD= 1.78 µg/ 
mL) was higher than before (Mean= 5.14 µg/mL; SD= 2.25 µg/mL) and it was statistically 
significant (p = 0.001). Hs-CRP level after Simvastatin 20 mg administration (Mean= 2.04 
mg/L; SD= 0.80 mg/L) was lowered than before (Mean= 7.82 mg/L; SD= 1.15 mg/L) and it was 
statistically significant (p= 0.001). 
Conclusion: Simvastatin administration increases NO serum levels and reduce hs-CRP level in 
patients with liver cirrhosis. 
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BACKGROUND 
The prevalence of liver cirrhosis (SH) 
worldwide is at the seventh place as the 
cause of death. About 25,000 people die 
each year from this disease. The preva-
lence of SH disease can cause about 
35,000 annual deaths in the United States 
(US) Cirrhosis is the ninth leading cause 
of death in the US and is responsible for 1-
2% of all deaths in the US. 
Many patients die in the fourth or 
fifth decade of their lives due to this 
disease (Bosch et al., 2003). There is no 
official national data on SH in Indonesia. 
But from some reports in government 
hospitals in Indonesia based on clinical 
course, it can be seen that the prevalence 
of SH treated in internal medicine gene-
rally ranges from 3.6 to 8.4% in Java and 
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Sumatra, while Sulawesi and Kalimantan 
are under 1% (Agus, 2007). 
Some clinical and experimental 
studies have found endothelial dysfunc-
tion in cirrhosis of the liver as indicated 
by a decrease in NO levels. The cause of 
the decline in this level is still not clearly 
known, it is thought there is a connection 
with the hyperdynamic circulation and the 
presence of endotoxemia that is common 
in liver cirrhosis. Endothelial dysfunction 
can affect imbalances between factors of 
relaxation and contraction, between pro-
coagulant mediators and anticoagulants 
or between substances that inhibit and 
promote growth. Biochemical markers 
commonly used for the determination of 
endothelial dysfunction as well as impro-
vement in endothelial function, one of 
which is NO (Yu et al., 2000). 
Another important thing is the find-
ing that the use of simvastatin prepara-
tions can improve the function of eNOS. 
The use of statin preparations can 
increase NO levels and improve endo-
thelial dysfunction in patients with SH 
and the use of statin preparations can 
reduce levels of hs-CRP (Ansell, 2003). 
There are limitations to the use of 
conventional therapy with β-blockers and 
the unsatisfactory results with isosorbid-
mononitrate therapy as a replacement 
therapy so that the pleotropic effects of 
simvastatin are expected to contribute to 
therapy in the state of HP in patients with 
SH (Ritzel et al., 2002). 
The number of HP events and the 
presence of disturbances in NO levels in 
SH patients, made the researchers focus 
this study on the effect of simvastatin on 
NO levels and hs-CRP levels in patients 
with SH. 
 
 
 
SUBJECTS AND METHOD 
1. Study Design 
This was a randomized controlled trial. A 
sample of 30 patients with liver cirrhosis 
divided into 15 patients with simvastatin 
20 mg/day and 15 patients with placebo. 
Samples of patients up to completion of 
the study were 29 patients divided into 14 
patients with simvastatin and 15 patients 
with placebo. 
This study was conducted in Depart-
ment of Internal Medicine, Faculty of 
Medicine, Universitas Sebelas Maret/ Dr. 
Moewardi hospital, Surakarta, from July 
to November 2018. Samples taken were 
SH patients who routinely control each 
month at the Gastroenterohepatology Cli-
nic as well as patients treated in the ward 
dr. Moewardi hospital Surakarta, which 
was taken randomly and fulfilled the 
inclusion and exclusion criteria and was 
willing to take part in the study by signing 
a blank agreement. Then the sample was 
divided into two groups, each of which 
consisted of 15 patients. Group I were 
patients given a placebo (control), group 
II were patients who were given simvas-
tatin 20 mg / day (therapy). 
The dose of simvastatin given is 20 
mg / day. Blood collection techniques and 
handling of specimens where NO and hs-
CRP tests were performed both before and 
after the treatment. NO examination was 
carried out by taking blood samples 
through the antecubital vein with a quiet 
room with controlled temperature (24-
250C), blood taken with a 3 cc citrate tube 
and then alternating slowly 10 times until 
homogeneous. Centrifug 3000 g for 10 
minutes, immediately separate the plasma 
into 3 cup samples @0.3 cc of plasma. 
Enter the identity, name, date and type of 
examination. Store at –20 0C (3 months 
stability). Blood processing and NO 
checks are carried out in collaboration 
with Prodia Clinical Laboratories. The 
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reagent kit used for Nitrate/Nitrite Colori-
metric Assay is a product of the Cayman 
Chemical Company, Ann Arbor, MI 48-
108, USA, Cat: 780001, Lot: 0458197. 
On HsCRP examination (Immuno-
chemiluminescent Method): Diluted 
samples, ligand labeled anti-CRP mono-
clonal antibodies were included in the unit 
test containing anti-ligand, and incubated 
for 30 minutes at 37C with occasional 
shaking. During shaking, CRP in the 
sample forms a sandwich antibody com-
plex that binds to the anti-ligand in the 
solid phase. The non-bonded conjugate 
was removed in spinning washing, then 
added the substrate and the test unit was 
incubated for 10 minutes. Chemilumines-
cent substrates, phosphate esters of ada-
mantyldioxetan, undergo hydrolysis in the 
presence of alkaline phosphatase produce 
continuous light emission, thus improving 
precision by providing multiple reading 
windows. The complex bonds and photons 
produced, measured by luminosity are 
proportional to the CRP concentration in 
the sample. 
 
RESULTS 
Simvastatin significantly increaseserum 
NO levels (Mean= 7.93µg/mL; SD= 1.78 
µg/mL) than before (Mean= 5.14µg/mL; 
SD= 2.55µg/mL) and it was statistically 
significant (p= 0.001). Simvastatin 
decreased hs-CRP levels (Mean= 2.04 
mg/L; SD= 0.80 mg/L) than before 
(Mean= 7.82 mg/L; SD= 1.15 mg/L) and it 
was statistically significant (p= 0.001). 
Table 1.The results of t test   
Independent 
Variables 
Treatment Control 
p 
Mean SD Mean SD 
SGOT 88.64 78.50 106.93 94.79 0.847 
SGPT 153.07 45.66 56.80 52.59 0.331 
Ureum 53.07 45.66 52.67 39.35 0.949 
Kreatinin 1.17 0.29 1.22 0.54 0.767 
Albumin 3.09 0.73 2.91 0.56 0.464 
Bilirubin1 1.04 0.69 0.84 0.47 0.477 
Bilirubin2 0.66 0.40 0.76 0.49 0.377 
Bilirubin total 1.70 1.06 1.60 0.85 0.847 
PT 15.81 1.85 16.73 4.35 0.474 
INR 1.29 0.30 1.40 0.51 0.591 
CN_test 93.79 21.81 91.00 29.19 0.774 
 
 
Figure 1. Nitric Oxide Level between Treatment and Control Groups 
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Figure 2. Hs-CRP Level between Treatment and Control Groups 
Table 2.The Result of Analysis of 2 Mean Difference Test  
Independent Variables 
Before  After  
p 
Mean SD Mean SD 
NO 5.14 2.55 7.93 1.78 0.001 
Hs-CRP 7.82 1.15 2.04 0.80 0.001 
 
DISCUSSION 
This study showed that the treatment 
group experienced a significant increase 
in nitric oxide (NO) compared to the 
control group and the administration of 
simvastatin could increase NO levels in 
liver cirrhosis. This condition was caused 
by liver cirrhosis portal hypertension (HP) 
which would act as an Associated Mole-
cular Pattern (DAMP) Damage which 
would be captured by the Antigen Pro-
cessing and Presenting Cell (APC) through 
the TollLike Receptor-9 (TLR 9) pathway 
and would be presented through MHC II, 
this incident would change the balance on 
Th1 which would produce Colony Stimu-
lating Factor (CSF) and Interferon-γ (IFN-
γ). CSF would activate neutrophils, and 
IFN-γ would activate macrophages to 
secrete pro-inflammatory cytokines such 
as TNF-α, Interleukin (IL-1, IL-6, and IL-
8). This condition was the incidence of 
low grade inflammation in liver cirrhosis 
and can cause endothelial dysfunction 
(Guntur, 2008), endothelial dysfunction 
would trigger oxidative stress resulting in 
decreased production of nitric oxide levels 
(Rajat et al.,2003). 
The administration of simvastatin in 
treated patients significantly increased 
NO levels because it would inhibit Rho 
geranylgeranylation and thus trigger the 
stability of eNOS mRNA and simvastatin 
triggered upregulation of eNOS (Laufs et 
al., 2000). According to research, statins 
have the ability of anti-oxidants so that 
they were capable of being inhibitors of κβ 
kinase (IKK) so that NFκβ activation was 
inhibited and triggers a decrease in oxi-
dative stress (Guntur, 2008). Simvastatin 
also decreased Rac1's membrane under 
basal conditions thereby reducing angio-
tensin II. A decrease in angiotensin II 
would reduce the activation of Angioten-
sin 1 receptors (AT1) and reduce Reactive 
Oxygen Species ROS in vitro and in vivo 
(Diez et al., 2010). Statins would improve 
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endothelial dysfunction due to oxidative 
stress and increase NO in various ways 
(Suciu, 2009). Trocha et al. (2010) also 
reported that simvastatin would increase 
eNOS. This study showed that the treat-
ment group had a tendency to decrease 
hs-CRP levels compared to the control 
group.  
There was study that was in line with 
this study regarding the use of simvastatin 
preparations which have antioxidant abi-
lity so that they were capable of inhibiting 
κβ kinase (IKK) to decrease oxidative 
stress. Simvastatin also decreased Rac1 
membrane under basal conditions thereby 
reducing angiotensin II. A decrease in 
angiotensin II would reduce the activation 
of Angiotensin 1 receptors (AT1) and 
reduce Reactive Oxygen Species ROS in 
vitro and in vivo (Diez et al., 2010).  
Suciu (2009) stated that statins 
would improve endothelial dysfunction 
due to oxidative stress and reduce hs-CRP 
levels in various ways. Wright et al. (2014) 
stated that simvastatin would increase 
eNOS which lead to an increase in NO. 
The effect of NO vasodilation was 
expected to reduce hs-CRP levels. There-
fore, the administration of Statins (3-
Hydroxy-3-methylglutary-co-enzyme A 
reductase inhibitors) can reduce intra-
hepatic vascular resistance and improve 
hepatic blood flow in the presence of 
vasodilation in liver cirrhosis. This was 
mediated by an increase in NO production 
due to improved vascular endothelium by 
increasing endothelial Nitric Oxide Syn-
tase (eNOS). It was expected that statins 
can repair endothelium in liver tissue for 
NO production, so that these preparations 
can be used as selective vasodilators of 
portal hypertension in liver cirrhosis 
(Francoz et al.,2010). 
This study aimed to investigate a 
relationship between changes in NO levels 
and hsCRP levels in the treatment with 
simvastatin supplementation. The results 
of the study indicated that there was a 
negative relationship between the NO 
variable and the hs-CRP level variable 
significantly. It can be interpreted that if 
the NO variable was improved or has 
increased, the tendency of hs-CRP tends 
to decrease which mean that improve-
ment in port hypertension has occurred, 
this was in accordance with the study of 
Wiest et al. CRP resulting in portal venous 
vasodilation and improvement of portal 
hypertension in liver cirrhosis. 
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